'Braf mutation' presentation slideshows

ASCO 2010 Neue Daten von Erbitux

ASCO 2010 Neue Daten von Erbitux. ASCO 2010 ERBITUX CRC - Orals. #3502 Oral Presentation, Maughan et al.,

2.49k views • 232 slides

899 views • 67 slides

Michael F Driscoll, MD Chief Fellow Medical Oncology / Hematology JGBCC University of Louisville

Update of 2010 American Society of Clinical Oncology (ASCO) Annual Meeting: Gastrointestinal Malignancies. Michael F Driscoll, MD Chief Fellow Medical Oncology / Hematology JGBCC University of Louisville. An Update on Gastrointestinal Cancer: Overview.

784 views • 58 slides

Research Presentation

Otorhinolaryngology: Head and Neck Surgery at PENN Excellence in Patient Care, Education and Research since 1870. Research Presentation. Jason M. Leibowitz, MD June 25, 2009 Preceptor: Marcia S. Brose, MD PhD . Overview. Background Hypothesis Methods Results Discussion

810 views • 39 slides

Research Presentation

Otorhinolaryngology: Head and Neck Surgery at PENN Excellence in Patient Care, Education and Research since 1870. Research Presentation. Jason M. Leibowitz, MD June 25, 2009 Preceptor: Marcia S. Brose, MD PhD . Overview. Background Hypothesis Methods Results Discussion

548 views • 39 slides

GIST Research at Fox Chase Cancer Center

GIST Research at Fox Chase Cancer Center. Margaret von Mehren, MD. 1.0. 0.9. 0.8. 0.7. 0.6. 0.5. 0.4. 0.3. 0.2. 0.1. 0. 10. 20. 30. Survival Following Recurrence or Metastases in GIST. Survival Probability. DFCI Data, 1995-2000. Time from Recurrence to Death (Months). TOTAL.

773 views • 36 slides

Maria Chiara Zatelli

296 views • 28 slides

Begin with BRAF

Begin with BRAF. Searching for a target in metastatic melanoma?. Overview. Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive 1 One common BRAF mutation (BRAF V600 ) is implicated in diverse malignancies 2,3

696 views • 14 slides